Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Acarbose vs Metformin: they're closely matched on evidence (4 vs 4/10); they're alternatives for manage blood sugar — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Acarbose and Metformin are closely matched across evidence, studies, and safety.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (1)
Outcomes where both Acarbose and Metformin have evidence — compare verdict strength side-by-side.
Off-label use mirrors diabetes dosing: taken with the first bite of carbohydrate-containing meals, titrated from a low dose (e.g. 25 mg) up to 50–100 mg per meal as GI tolerance allows. A prescription drug, not an approved longevity regimen.
with-meals
Oral tablet with meals
Off-label longevity use mirrors diabetes dosing (commonly 500–1500 mg/day of extended-release with meals) under a clinician. Not an approved longevity regimen, and unnecessary in well-controlled non-diabetics without a clear rationale.
with-meals
Extended-release tablet
Unknown in humans
Years
Per meal
With each carb-containing meal
Weeks
Years
Weeks of training
Days (GI) to years (B12)
Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α-glucosidase inhibitor or a Nrf2-inducer.
Aging cell (2016) · Animal
NIA ITP study: acarbose extended lifespan, most strongly in male genetically heterogeneous mice
Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data.
Diabetologia (2004) · Rct · n=1429
STOP-NIDDM randomized trial in impaired-glucose-tolerance adults
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
JAMA (2003) · Rct
Randomized analysis of acarbose and cardiovascular/hypertension risk
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Lancet (London, England) (1998) · Rct · n=753
UKPDS 34 randomized trial of metformin in overweight type-2 diabetics
Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: A systematic review and meta-analysis.
Ageing research reviews (2017) · Meta analysis
Systematic review/meta-analysis of metformin and age-related outcomes
Metformin as a Tool to Target Aging.
Cell metabolism (2016) · Review
Review of metformin's aging-relevant mechanisms (AMPK, insulin/IGF-1, inflammation)
Both Acarbose and Metformin are closely matched — the best choice depends on your specific health goals.
For manage blood sugar, Metformin has a higher relevance score (72 vs 60).
No known interactions between Acarbose and Metformin have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.